vs
Side-by-side financial comparison of Dayforce (DAY) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Dayforce is the larger business by last-quarter revenue ($481.6M vs $281.3M, roughly 1.7× Guardant Health, Inc.). Dayforce runs the higher net margin — -40.9% vs -45.7%, a 4.8% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 9.5%). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 9.8%).
Dayforce, Inc., formerly Ceridian, is an American human resources software and services company.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
DAY vs GH — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $481.6M | $281.3M |
| Net Profit | $-196.8M | $-128.5M |
| Gross Margin | — | 64.6% |
| Operating Margin | 6.3% | -43.0% |
| Net Margin | -40.9% | -45.7% |
| Revenue YoY | 9.5% | 39.4% |
| Net Profit YoY | -9940.0% | -15.8% |
| EPS (diluted) | $-1.23 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $281.3M | ||
| Q3 25 | $481.6M | $265.2M | ||
| Q2 25 | $464.7M | $232.1M | ||
| Q1 25 | $481.8M | $203.5M | ||
| Q4 24 | $465.2M | $201.8M | ||
| Q3 24 | $440.0M | $191.5M | ||
| Q2 24 | $423.3M | $177.2M | ||
| Q1 24 | $431.5M | $168.5M |
| Q4 25 | — | $-128.5M | ||
| Q3 25 | $-196.8M | $-92.7M | ||
| Q2 25 | $21.3M | $-99.9M | ||
| Q1 25 | $14.9M | $-95.2M | ||
| Q4 24 | $10.8M | $-111.0M | ||
| Q3 24 | $2.0M | $-107.8M | ||
| Q2 24 | $-1.8M | $-102.6M | ||
| Q1 24 | $7.1M | $-115.0M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | 47.0% | 61.6% | ||
| Q3 24 | 45.8% | 61.1% | ||
| Q2 24 | 44.1% | 59.1% | ||
| Q1 24 | 47.6% | 61.2% |
| Q4 25 | — | -43.0% | ||
| Q3 25 | 6.3% | -37.3% | ||
| Q2 25 | 9.1% | -45.9% | ||
| Q1 25 | 6.4% | -54.6% | ||
| Q4 24 | 6.1% | -62.4% | ||
| Q3 24 | 4.7% | -61.3% | ||
| Q2 24 | 3.3% | -56.8% | ||
| Q1 24 | 9.4% | -59.2% |
| Q4 25 | — | -45.7% | ||
| Q3 25 | -40.9% | -35.0% | ||
| Q2 25 | 4.6% | -43.0% | ||
| Q1 25 | 3.1% | -46.8% | ||
| Q4 24 | 2.3% | -55.0% | ||
| Q3 24 | 0.5% | -56.3% | ||
| Q2 24 | -0.4% | -57.9% | ||
| Q1 24 | 1.6% | -68.2% |
| Q4 25 | — | $-1.01 | ||
| Q3 25 | $-1.23 | $-0.74 | ||
| Q2 25 | $0.13 | $-0.80 | ||
| Q1 25 | $0.09 | $-0.77 | ||
| Q4 24 | $0.07 | $-0.90 | ||
| Q3 24 | $0.01 | $-0.88 | ||
| Q2 24 | $-0.01 | $-0.84 | ||
| Q1 24 | $0.04 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $627.6M | $378.2M |
| Total DebtLower is stronger | $631.1M | $1.5B |
| Stockholders' EquityBook value | $2.7B | $-99.3M |
| Total Assets | $8.7B | $2.0B |
| Debt / EquityLower = less leverage | 0.23× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $378.2M | ||
| Q3 25 | $627.6M | $580.0M | ||
| Q2 25 | $625.2M | $629.1M | ||
| Q1 25 | $557.3M | $698.6M | ||
| Q4 24 | $579.7M | $525.5M | ||
| Q3 24 | $494.1M | $585.0M | ||
| Q2 24 | $465.4M | $933.7M | ||
| Q1 24 | $392.5M | $1.0B |
| Q4 25 | — | $1.5B | ||
| Q3 25 | $631.1M | $1.1B | ||
| Q2 25 | $631.8M | $1.1B | ||
| Q1 25 | $632.4M | $1.1B | ||
| Q4 24 | $1.2B | $1.1B | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.2B | — |
| Q4 25 | — | $-99.3M | ||
| Q3 25 | $2.7B | $-354.5M | ||
| Q2 25 | $2.7B | $-305.5M | ||
| Q1 25 | $2.6B | $-250.8M | ||
| Q4 24 | $2.5B | $-139.6M | ||
| Q3 24 | $2.6B | $-60.1M | ||
| Q2 24 | $2.5B | $-1.6M | ||
| Q1 24 | $2.4B | $68.3M |
| Q4 25 | — | $2.0B | ||
| Q3 25 | $8.7B | $1.3B | ||
| Q2 25 | $8.5B | $1.3B | ||
| Q1 25 | $9.5B | $1.3B | ||
| Q4 24 | $9.1B | $1.5B | ||
| Q3 24 | $8.1B | $1.5B | ||
| Q2 24 | $9.0B | $1.6B | ||
| Q1 24 | $10.8B | $1.7B |
| Q4 25 | — | — | ||
| Q3 25 | 0.23× | — | ||
| Q2 25 | 0.23× | — | ||
| Q1 25 | 0.24× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | 0.50× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.2M | $-26.4M |
| Free Cash FlowOCF − Capex | — | $-54.2M |
| FCF MarginFCF / Revenue | — | -19.3% |
| Capex IntensityCapex / Revenue | — | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-26.4M | ||
| Q3 25 | $31.2M | $-35.4M | ||
| Q2 25 | $112.7M | $-60.3M | ||
| Q1 25 | $49.6M | $-62.7M | ||
| Q4 24 | $81.0M | $-64.5M | ||
| Q3 24 | $91.8M | $-51.1M | ||
| Q2 24 | $99.2M | $-94.0M | ||
| Q1 24 | $9.1M | $-30.3M |
| Q4 25 | — | $-54.2M | ||
| Q3 25 | — | $-45.8M | ||
| Q2 25 | — | $-65.9M | ||
| Q1 25 | — | $-67.1M | ||
| Q4 24 | — | $-83.4M | ||
| Q3 24 | — | $-55.3M | ||
| Q2 24 | — | $-99.1M | ||
| Q1 24 | — | $-37.2M |
| Q4 25 | — | -19.3% | ||
| Q3 25 | — | -17.3% | ||
| Q2 25 | — | -28.4% | ||
| Q1 25 | — | -33.0% | ||
| Q4 24 | — | -41.3% | ||
| Q3 24 | — | -28.9% | ||
| Q2 24 | — | -55.9% | ||
| Q1 24 | — | -22.1% |
| Q4 25 | — | 9.9% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 9.4% | ||
| Q3 24 | — | 2.2% | ||
| Q2 24 | — | 2.9% | ||
| Q1 24 | — | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 5.29× | — | ||
| Q1 25 | 3.33× | — | ||
| Q4 24 | 7.50× | — | ||
| Q3 24 | 45.90× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DAY
| Dayforce Recurring | $333.0M | 69% |
| Cloud And Bureau Professional Services And Other | $78.5M | 16% |
| Float | $42.2M | 9% |
| Powerpay Recurring | $19.7M | 4% |
| Other Recurring | $8.2M | 2% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
